Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Moderna seeks FDA blessing for second COVID-19 vaccine booster

By Brian Buntz | March 18, 2022

ModernaPfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) recently asked FDA to allow individuals 65 and older to receive a second booster of their BNT162b2 COVID-19 vaccine.

Now, Moderna (Nasdaq:MRNA) is filing for FDA authorization to permit a fourth dose of its Spikevax (mRNA-1273) COVID-19 vaccine for adults 18 and older.

In its submission, Moderna included data gathered from the U.S. and Israel after the emergence of the omicron variant.

Data on the efficacy of a fourth dose of Moderna’s vaccine against omicron were recently published in NEJM. The researchers, considering data from the Moderna and Pfizer-BioNTech vaccines, concluded that a fourth dose of mRNA vaccine appears to be “immunogenic, safe, and somewhat efficacious (primarily against symptomatic disease).”

In January, early data from Israel’s Sheba Medical Center indicated that an additional booster of COVID-19 vaccine from Pfizer and BioNTech drove to a fivefold increase in antibodies one week after administration of the vaccine.

FDA approved Moderna’s COVID-19 vaccine on January 31. A primary series of the vaccine consists of two 100 µg doses of the vaccine.

The agency permitted a 50 µg booster dose of the vaccine under emergency use authorization. FDA also allows a 100 µg booster for moderately to severely immunocompromised individuals.

Moderna’s most recent request would amend the emergency use authorization pertaining to booster doses of the vaccine.

Moderna continues to develop an omicron-specific booster known as mRNA-1273.529 and a bivalent omicron-specific booster known as mRNA-1273.214.

In April, the FDA will convene a meeting of its advisory committee, the Vaccines and Related Biological Products Advisory Committee.


Filed Under: Infectious Disease, Uncategorized
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccines, Moderna
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Trikafta wins Canadian approval for Trikafta in children with cystic fibrosis
Novartis
Novartis partners with Carisma Therapeutics on manufacturing HER2-targeted CAR-M cell therapy
Medicago and GSK
Medicago and GSK win approval from Health Canada for adjuvanted plant-based COVID-19 vaccine
Biogen/Xbrane
Biogen announces biosimilars collaboration deal with Xbrane

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50